 |
인쇄하기
취소
|
Viread takes on Baraclude
Yuhan Corp. is enjoying brisk sales of its new anti-hepatitis B drug, Viread (tenofovir) developed by Gilead Sciences as a nucleotide reverse transcriptase inhibitor.
According to IMS data, sales of Viread reached over 17 billion won since its coverage by national health insurance in December 2012, making it one of the top-selling drugs in the country.
Since the introduction of Viread, o...
According to IMS data, sales of Viread reached over 17 billion won since its coverage by national health insurance in December 2012, making it one of the top-selling drugs in the country.
Since the introduction of Viread, o...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.